Information Provided By:
Fly News Breaks for March 25, 2019
AIMT
Mar 25, 2019 | 10:49 EDT
Piper Jaffray analyst Christopher Raymond says that while details were limited with the data embargoed, he views this morning's announcement from Aimmune Therapeutics as "de-risking." It provides another set of Phase 3 safety and efficacy data for AR101, Raymond tells investors in a research note. He expects more clarity in June when the data are presented, but adds that management commentary indicates efficacy and safety are in line with the Phase 3 Palisade data. Raymond continues to like the set-up for the shares and remains a buyer of Aimmune with an Overweight rating and $60 price target.
News For AIMT From the Last 2 Days
There are no results for your query AIMT